STAAR Surgical shares jump 18.3% after Q1 revenue and EPS beat estimates

STAAR Surgical (NASDAQ: STAA) shares rose 18.3% to $34.77 on May 13, 2026, after the medical lens maker reported first-quarter 2026 results that topped Wall Street expectations, led by a 120% year-over-year revenue increase. Revenue was $93.52 million, beating analyst estimates by 20.8%. GAAP earnings were $0.10 per share, above consensus and improved from a loss of $1.10 per share a year earlier. Adjusted operating margin was 13.7%, up sharply from the prior-year period. The results mark a rebound from recent weakness. STAAR’s revenue declined at a 5.7% annualized rate over the past two years, despite 10.2% annualized growth over five years. Analysts expect revenue to rise 7.1% over the next 12 months and forecast full-year EPS to swing from a projected loss of $0.43 to a profit of $0.22.